Latham Advises Astorg On Acquisition of CordenPharma

Latham & Watkins has advised Astorg, a leading European private equity firm, on its binding agreement to acquire CordenPharma, a leading pharmaceutical contract development and manufacturing organization, from International Chemical Investors Group (ICIG), a privately owned industrial group.

CordenPharma serves more than 250 blue-chip pharma and biotech customers across five technology platforms: Peptides, Lipids & Carbohydrates (notably lipids for mRNA vaccines and therapeutics), Highly Potent & Oncology, Injectables and Small Molecules. It provides distinctive know-how, an integrated product offering and end-to-end capabilities from early-stage development to commercial large-scale manufacturing, and has experienced strong organic growth.

The Latham team was led by Frankfurt, Milan, London and Paris corporate teams comprising partners Thomas Forschbach, Maximilian Platzer, Stefano Sciolla, and Simon Lange, counsel Hanno Witt, and associates Adrien Levallois, Hendrik Ley, Christos Ierna, Jaschar Mirkhani, Florian Feistle, Nikolaus Becker, Andrea Stincardini, and Edoardo Cassinelli.  Advice was provided on life sciences matters by Paris partner Eveline Van Keymeulen and Paris associate Jeanne Fabre; on IP matters by Paris partner Jean-Luc Juhan and London partner Andrew Moyle, with London associates Sara Patel and Oscar Bjartell; and on antitrust/FDI matters by Paris partner Mathilde Saltiel, Washington D.C. partner Damara Chambers, and Hamburg counsel Jana Dammann.